Medical Marijuana Market Opportunities by Types, Demand, Top Manufactures and Application in Grooming Regions

The global medical marijuana market is expected to witness considerable growth during the forecast period on account of the rise in the number of countries legalizing the consumption of the drug for medicinal purposes and its potential application in the treatment of several chronic diseases. Increasing awareness among healthcare providers and individuals regarding the benefits of medicinal marijuana will also support the market growth in the future. Moreover, growing investments (by both private and public organizations) in research associated with the use of marijuana for medical purposes are expected to continue driving the market growth.

On the basis of application, the medical marijuana market is categorized into chronic pain, arthritis, migraine, cancer, and others. Among these, chronic pain is the largest application area of medical marijuana and is expected to continue leading the market during the coming years. This can be attributed to the increasing prevalence of chronic diseases and rising awareness among patients and healthcare providers regarding the potential benefits of using marijuana for relieving chronic pain.

Request to Get the Sample Pages at:

Globally, North America was the largest revenue generator in the medical marijuana market in 2017, because of high investments in research and development activities to investigate the potential medical applications of cannabinoids. Moreover, Canada and some states of the U.S. are planning to legalize the usage of marijuana for medical as well as recreational purposes. For instance, by October 2018, Canada plans to legalize the drug use by adults. As per the current medical regime associated with cannabis, patients are allowed to access cannabis under the authorization of their healthcare providers. 

Thus, government initiatives to spread awareness about the medical application of marijuana and legalize its usage are expected to contribute to the market growth in the near future.

Some of the major factors contributing to the growth of the medical marijuana industry are the increasing prevalence of chronic diseases, growing investments by public and private organizations to conduct research focusing on the medical applications of marijuana, and rising awareness among healthcare providers toward the usage of the drug.

Make Enquiry Before Buying the Report: https://www.psmarketresearch.com/send-enquiry?enquiry-url=medical-marijuana-market

Several research projects have been funded by the National Institute of Health (NIH) and the National Institute on Drug Abuse (NIDA) to explore the possible benefits of marijuana in different medical conditions. Furthermore, increasing consumption of cannabinoid-based drugs approved for certain disorders is promoting the market growth. For instance, nabiximols (Sativex), a mouth spray containing two cannabinoids of marijuana, that is, tetrahydrocannabinol (THC) and cannabidiol (CBD), is used for treating muscle control problems caused by multiple sclerosis. Nabiximols is approved in the U.K., Canada, and several European countries, and studies are being conducted for the drug approval in the U.S. as well.

Players, through the acquisition of other similar companies, are strengthening their position in the medical marijuana market. For instance, in October 2018, Wuhan General Group [China] Inc. (Wuhan) announced that it signed a letter of intent to acquire MJ MedTech Inc. (MedTech), a manufacturer of medical marijuana and cannabidiol (CBD) products. Through this acquisition, Wuhan expects to gain from MedTech’s insights, market value, and advanced technology to establish its presence in the U.S., Canadian, and European markets and strengthen its position in the medical CBD product business.

Some of the other key players in the medical marijuana industry are Canopy Growth Corporation, Aurora Cannabis Inc., Medical Marijuana Inc., GW Pharmaceuticals PLC, Aphria Inc., CanniMed Ltd., Tilray Inc., and Emerald Health Therapeutics Inc.

Read More

Diabetic Retinopathy Market Comprehensive Review of its Applications Growth Opportunities and Future Prospects

Diabetic retinopathy refers to an eye disorder that damages or harms the blood vessels of the retina. Diabetic retinopathy can cause permanent blindness. Chronic diabetes is a major root of diabetic retinopathy.

The treatment procedure of diabetic retinopathy depends on the various stages of diabetic retinopathy. It is one of the most dominant reasons of blindness in U.S adults. According to WHO, about 347 million patients were suffering from diabetes globally as of 2012, and among those 347 million patients 11% of those were effected from diabetic retinopathy.  In the U.S. alone, there were 4.1 million people were impacted from the diabetic retinopathy as of 2012. 

 Request to Get the Sample Pages at: 

North America was the largest market for diabetic retinopathy in 2014. The market dominance of North America is attributed to the high obesity rate and large diabetic patients in this region. Moreover the supportive government initiative is also one of the important drivers of the market in this region.

Europe was the second largest market of diabetic retinopathy in 2014, the large population of baby boomers in Europe is one of the dominate growth factors for the diabetic retinopathy market in this region. Asia Pacific is expected to show the highest growth over the next five years. The lucrative growth of the diabetic retinopathy market in Asia Pacific is attributed to the presence of a large number of diabetic patients in India and China. Moreover, growing health awareness coupled with rising expenditure on healthcare services is also fueling the diabetic retinopathy market in this region. Country wise the U.S. is the largest market of diabetic retinopathy in North America. Germany, Spain, Italy, U.K and France are some of the major diabetic retinopathy market in Europe. China, Japan, India are some of the major market diabetic retinopathy in Asia Pacific region. Under Rest of the World section Brazil is the largest market of diabetic retinopathy.   

Make Enquiry Before Buying the Report: https://www.psmarketresearch.com/send-enquiry?enquiry-url=diabetic-retinopathy-market

  

Some of the major players operating in the global diabetic retinopathy market include, Bayer AG, Pfizer Inc., F. Hoffmann-La Roche Ltd., Regeneron Pharmaceuticals Inc., Novartis AG, Valeant Pharmaceuticals International Inc., Abbott Laboratories Ltd., Alimera Sciences Inc., Ampio Pharmaceuticals Inc., Bausch & Lomb Inc., Boehringer Ingelheim GmbH, iCo Therapeutics Inc., Lupin Ltd., Parexel International Corp., Quark Pharmaceuticals Inc., Thrombogenics NV, and Vitreoretinal Technologies Inc. 

Read More

Diabetic Nephropathy Market Opportunities by Types, Demand, Top Manufactures and Application in Grooming Regions

The increase in research and development funds for drug discovery followed by growing awareness of kidney-related disorders, and diabetes are the major factors driving the expansion of the global diabetic nephropathy market.

Diabetes is a disease defined by high blood sugar level, caused by inappropriate functioning of the pancreas (the organ which secretes insulin in the body). Nephropathy means kidney impairment or damage. Diabetic nephropathy is the impairment or damage to the kidneys caused by diabetes.

It is a disease which affects the kidney glomerulus and one of the most major issues for diabetic patients. Not only the person with diabetes has to undergo kidney impairment, but also the acute cases of diabetic nephropathy could lead to kidney miscarriage. The disease affects the kidneys in a way that makes it futile. Progressive growth in proteinuria and failure in renal function, hypertension, and high risk of cardiovascular disease are the major side effects of chronic diabetic nephropathy. Blood pressure (BP) control is necessary in minimizing the progression of diabetic nephropathy. Irrespective of the agent used, lower blood pressure in type II diabetics could slow down the start and progression of diabetic nephropathy.

Request to Get the Sample Pages at:

On the basis of mode of treatment, the global diabetic nephropathy market is segmented into disease modifying therapies and others. Disease modifying therapies is further categorized into diuretics, angiotensin-converting enzyme inhibitors, antioxidant inflammation modulator, angiotensin receptor blockers, renin inhibitors, calcium channel blockers, connective tissue growth factor inhibitors, monocyte chemoattractant proteins inhibitor, G protein-coupled receptors and endothelin (a receptor antagonist).

Make Enquiry Before Buying the Report: https://www.psmarketresearch.com/send-enquiry?enquiry-url=diabetic-nephropathy-market

Various government programs are spreading cognizance about diabetes and related renal complications in North America. For example, the National Kidney Disease Education Program (NKDEP) is one of the most important programs organized by the U.S. government, for growing awareness about the various kidney diseases.

Lack of complete therapeutic management for diabetic nephropathy, longer approval time for drugs as well as, harsh regulatory requirements are hampering the market growth of global diabetes nephropathy market.

Some of the major competitors in the global diabetic nephropathy market are Novartis AG, Merck & Co., Inc., Pfizer Inc., Abbott Laboratories, Sanofi, Eli Lilly and Company, Reata Pharmaceuticals, Inc., Bayer AG, AbbVie Inc., and Mitsubishi Tanabe Pharma Corporation.

Read More

Contraceptives Market Drug Profile, Top Industry Intelligence and Therapeutic Development

The global contraceptives market is growing significantly due to increasing incidences of unwanted pregnancies, increasing prevalence of sexually transmitted diseases and advances in contraception techniques. In addition, government and non-government organizations are funding and supporting programs to encourage contraception. Large unexplored contraceptives market in emerging economies is creating ample opportunities for the global contraceptives market to grow at a considerable rate in the coming years. Several major players in the contraception market are actively involved in the research and new product development for contraception, which could meet the demand of cost effective long term contraception.

Contraception is a method used to prevent pregnancy. Several contraceptives, such as hormonal drugs, physical barriers, and advanced contraceptive devices have been developed in order to prevent unwanted pregnancy. Contraceptives also help in preventing sexually transmitted infections. According to a report published by Guttmacher Institute, a non-profit organization working in advance sexual and reproductive health, 213.4 million pregnancies occurred across the globe in 2012, of which 40.0% were unintended. Also, high number of sexually transmitted infection is a major concern across the globe. According to the WHO, in 2013, 35.0 million people lived with HIV/AIDS and 1.5 million people died due to AIDS –related illness worldwide. The organization also reported that an estimated 500 million new curable sexually transmitted infections (including chlamydia, gonorrhoea, syphilis and trichomoniasis only) occur across the globe each year.

Request to Get the Sample Pages at: 

The global contraceptives market is categorized as devices and drugs. Based on devices, the contraceptives market is categorized as contraceptive sponges, vaginal rings, contraceptive diaphragms, intrauterine devices (IUDs), subdermal implants, male condoms, female condoms, and others. The IUDs segment is further categorized as hormonal IUDs and copper IUDs. On the basis of drugs, the contraceptive market can be categorized as topical contraceptives, injectable contraceptives, and oral contraceptives or pills. Contraceptive pills lead the global contraceptive drugs market due to its convenience in use and high efficiency in emergency contraception.

Make Enquiry Before Buying the Report: https://www.psmarketresearch.com/send-enquiry?enquiry-url=contraceptives-market

Geographically, North America leads the global contraceptives market due to high awareness about contraception, high number of unwanted pregnancies, and increasing prevalence of sexually transmitted diseases among adolescents and young adults. In addition, inclusion of contraception in Patient Protection and Affordable Care Act as preventive services to be provided without co-payment by patient further drives the growth of global contraceptives market in North America region. 

Asia-Pacific is the fastest growing region in the global contraceptives market. The major reasons for the fastest growth in the region are increasing prevalence of sexually transmitted diseases, high unintended pregnancies, and improving healthcare infrastructure. Moreover, the contraceptives market is growing rapidly due to the several government supported programs for promoting contraception in emerging economies, such as India and China, of Asia-Pacific region.

Some of the major players operating in the global Contraceptives market are Cooper Surgical Inc., Mayer Laboratories Inc., Merck & Co. Inc., Bayer AG, Actavis Inc., Reckitt Benckiser plc, Pfizer Inc., The Female Health Company, Church & Dwight Co., Inc., and Teva Pharmaceutical Industries Ltd.

Read More

Choroidal Neovascularization Market Analysis by Stages, Drug Class, Company Profile, Phase of Development

Choroidal neovascular are the new blood vessels that grow just below the retina and interrupt the vision. Choroid, which is responsible for oxygen and nutrients supply to the eye, is the area between the retina and the sclera, where the blood vessels grow and cause choroidal neovascularization (CNV). Choroidal neovascularization break the barrier between retina and choroid and the membrane leaks in the retina causing vision loss.

Choroidal neovascularization leads to various severe eye diseases such as histoplasmosis, eye trauma, wet age related macular degeneration and myopic macular degeneration. Myopic macular degeneration is generally found in aged people because of tremendous elongation of their eyeball, leading to loss of vision in them. Mostly, the causes for choroidal neovascular are idiopathic, infections, choroidal tumors, degeneration, and trauma.

Request to Get the Sample Pages at

Innovation of products with the focus on enhanced efficiency, and growing demographics and economies in the emerging countries such as China and India are some of the major opportunities for choroidal neovascularization market. Increasing prevalence of choroidal neovascularization cases, high patient and physician satisfaction, increasing aging population and rising government initiatives towards healthcare infrastructure in the developing countries are some of the major factors that are driving the growth of global choroidal neovascularization market. Additionally, increase incidences of lifestyle associated diseases such as high blood pressure and diabetes are also acting as a driver for the growth of global choroidal neovascularization (CNV) market.

Make Enquiry Before Buying the Report: https://www.psmarketresearch.com/send-enquiry?enquiry-url=choroidal-neovascularization-market

North America had the largest choroidal neovascularization (CNV) market in 2014, attributed to growing population of baby boomers and increasing incidences of choroidal diseases in the region. The Asia-Pacific choroidal neovascularization market is growing with the highest rate compared to the market in other regions. China and India are the two countries, in Asia-Pacific, witnessing fastest growth of choroidal neovascularization markets. Large population of these countries coupled with raising government initiatives and support are the major driving factors of choroidal neovascularization markets in this region.

Some of the major competitors in choroidal neovascularization CNV market are Bayer AG, Chengdu Kanghong Biotech Co. Ltd., Resolvyx Pharmaceuticals Inc., F. Hoffmann-La Roche Ltd., Valeant Pharmaceuticals International Inc., Promedior Inc., Mat Biopharma SAS, Quark Pharmaceuticals Inc., Novartis AG, and Gilead Sciences Inc.

Read More

Biosimilars Market Analysis by Stages, Drug Class, Company Profile, Phase of Development, Preclinical Research and Discovery Stage Insights

Biosimilars are complex biological products made from living organism that include microorganisms such as bacteria and yeast, humans, and animals. These biological products are similar biological product also known as biological reference product, that have been approved by the U.S. Food Drug and Administration (USFDA). Biosimilars are compared with the biological reference products and licensed by the USFDA. Patent expiration of biological reference product is the key factor leading to development of biosimilars. 

These are composed of complex molecules such as monoclonal antibodies and human insulin. Advanced technologies are involved in the development and manufacturing of biosimilars that include monoclonal antibody (MAb) technology, nuclear magnetic resonance (NMR)technology, recombinant DNA (r-DNA) technology, electrophoresis and bioassays. Monoclonal antibody technology and bioassay are most significant technologies for the development and validation of biosimilars. Most of the biologics, such as monoclonal antibodies, anticoagulants, and vaccines are large molecules which need to be administered parenterally to achieve the desired therapeutic effects. These complex biosimilars are used in prevention and treatment of diabetes, multiple sclerosis, cancer, rheumatoid arthritis, inflammatory bowel diseases, low white blood cell count, anemia, infectious diseases, chronic kidney failure and other health conditions and offers cost effective treatment than other synthetic and biological drugs.

  

Request to Get the Sample Pages at: 

Global Biosimilars market has been witnessing growth driven by increasing prevalence of chronic and autoimmune diseases, growing demand of cost-effective medicinal products and growing aging population. According to World Cancer Research Fund International, 14.1 million cancer cases were estimated in 2012 and is expected to increase to 24 million by 2035. Elderly people are more prone to chronic disease such as diabetes, rheumatoid arthritis chronic pain and other health conditions.

As per United Nations Department of Economic and Social Affairs (UNDESA) report on the global aging population, the population of people aged 60 years or above is growing at a high rate. The number of people aged 60 years or over is projected to grow by 56.0 % globally, i.e. from 901 million in 2015 to 1.4 billion by 2030, and it is projected to more than double its size from 2015, to reach 2.1 billion by 2050. In addition, increasing research and development investments, healthcare expenditures and technological advancement also drive the growth of biosimilars market. However, Stringent regulations and complex manufacturing process restricts the growth of biosimilars market. FDA and EMA along with World Health Organisation are actively regulating the development and validation of biosimilars. Countries such as Japan, South Africa, Australia, Canada, Korea have crafted their own regulatory guidelines for the development and validation of biosimilars.

Make Enquiry Before Buying the Report: https://www.psmarketresearch.com/send-enquiry?enquiry-url=biosimilars-market

Geographically, Europe is the largest market for biosimilars The European market for biosimilars is driven by increasing prevalence of chronic diseases, and various initiatives taken by the EMA and government to increase the awareness regarding new approaches and use of biosimilars. North America is the second largest market for biosimilars market, with the U.S. accounting for the largest revenue contribution to the North American market. Some of the key factors driving the revenue growth of the biosimilars market in North America include rise in the number of chronic and lifestyle diseases, increasing research and development investments and increasing healthcare expenditures. Private health insurance plays an important role in U.S. healthcare system, provides primary healthcare coverage to large population group leading to affordability of better healthcare facilities.  Asia-Pacific is expected to be the fastest growing market for biosimilars due to a rise in the population, increased government initiatives, availability of skilled labour, low manufacturing cost and growing medical tourism in Singapore, Thailand, India and Malaysia.

  

In October 2016, Teva Pharmaceuticals Industries Ltd. announced partnership with celltrion, Inc. and Celltrion Healthcare for the commercialization of proposed Monoclonal Antibody (MAb) biosimilars to Rituxan and Herceptin in the U.S. and Canada. Rituxan is used in the treatment of rheumatoid arthritis, and chronic lymphatic leukemia whereas Herceptin is used in the treatment of breast cancer.

In February 2016, Sandoz, a Novartis company announced acquisition of rights for the development and commercialization of PF06438179(biosimilar infliximab) in the European Economic Area (EEA) from Pfizer. Infliximab is used in the treatment of rheumatoid arthritis

MARKET SEGMENTAT

By Product

·         Monoclonal Antibodies

·         Human Growth Hormone

·         Insulin

·         Interferon

·         Erythropoietin

·         Granulocyte colony stimulating factor (G-CSF)

·         Peptides

·         Others

By Manufacturing type

·         Contract Manufacturing Organization

·         In-house Manufacturing

By Technology

·         Recombinant DNA Technology

·         Monoclonal Antibodies Technology

·         Nuclear Magnetic Resonance Technology

·         Chromatography

·         Bioassay

·         Others

By Application

·         Chronic autoimmune diseases

·         Oncology

·         Blood disorders

·         Growth Hormone Deficiency

·         Infectious Diseases

·         Other Applications

GEOGRAPHICAL SEGMENTATION

By Region

·         North America

o    U.S.

o    Canada

·         Europe

o    U.K.

o    Germany

o    France

o    Italy

o    Rest of Europe

·         Asia-Pacific

o    Japan

o    China

o    India

o    Rest of Asia-Pacific

·         Latin America

o    Brazil

o    Mexico

o    Rest of LATAM

o    Middle East Africa

Read More

Autoimmune Treatment Market Performance and Market Share, Sales Revenue and Major Manufacturers Performance, Gross Margin Analysis

The global autoimmune treatment market is growing significantly due to increasing incidences of autoimmune diseases, up surging healthcare expenditure, and advancements in the technologies for the development of autoimmune diseases therapeutics. Autoimmune diseases are chronic in nature and do not have permanent treatment. This creates ample growth opportunity for the autoimmune treatment market, to grow at a considerable rate in the coming years. The advanced research and development facilities, and new product developments by the companies are propelling the demand for cost effective treatment of autoimmune diseases. 

The abnormal response of immune system leads to autoimmune disorders. Normally, the body’s immune system provides protection against foreign bodies or harmful substances. However, in the autoimmune disorders, the immune system fails to differentiate between a healthy tissue or cell and a harmful substance (antigen), and destroys the normal tissues. Autoimmune diseases have high prevalence among female children and women. There are more than 80 prevailing autoimmune diseases. Some of the most common autoimmune disorders include psoriasis, multiple sclerosis, rheumatoid arthritis, type 1 diabetes, systemic lupus erythematosus, inflammatory bowel disease, and Addison’s disease.

Request to Get the Report Sample Pages at: 

Based on applications, the autoimmune treatment market can be categorized as type 1 diabetes, inflammatory bowel disease, multiple sclerosis, systemic lupus erythematosus, psoriasis, rheumatoid arthritis, thyroid disease, and others. Rheumatoid arthritis leads the global autoimmune treatment market, due to high prevalence of rheumatoid arthritis worldwide.

Make Enquiry Before Buying the Report: https://www.psmarketresearch.com/send-enquiry?enquiry-url=autoimmune-treatment-market

Geographically, North America leads the global autoimmune treatment market, due to aging population, high incidences of autoimmune diseases, increased healthcare expenditure, and excessive R&D investment for the development of drugs for autoimmune diseases. Asia-Pacific is the fastest growing region in the global autoimmune treatment market. The major reasons for the fastest growth in the region are increasing healthcare expenditure and improving healthcare infrastructure. Moreover, the autoimmune treatment market is growing, due to increasing disposable income and large population suffering from autoimmune diseases in the emerging countries, such as India and China.

Some of the major players operating in the global autoimmune treatment market are Abott, Bristol-Myers Squibb Company, Amgen Inc., Pfizer Inc., Bayer AG, F. Hoffmann-La Roche AG, Eli Lilly and Company, Novartis AG, Johnson & Johnson Services Inc., Merck & Co. Inc., Sanofi, GlaxoSmithKline PLC, Biogen, Boehringer Ingelheim GmbH, AstraZeneca PLC, and Astellas Pharma Inc.

About P&S Intelligence

P&S Intelligence, a brand of P&S Market Research, is a provider of market research and consulting services catering to the market information needs of burgeoning industries across the world. Providing the plinth of market intelligence, P&S as an enterprising research and consulting company, believes in providing thorough landscape analyses on the ever-changing market scenario, to empower companies to make informed decisions and base their business strategies with astuteness.

Contact:

P&S Intelligence

Toll-free: +1-888-778-7886 (USA/Canada)           

International: +1-347-960-6455

Email: enquiry@psmarketresearch.com

Web: https://www.psmarketresearch.com

Connect with us: LinkedIn | Twitter | Google + | Facebook

Read More